-
ARTIFICIAL INTELLIGENCE IN PHARMACOECONOMICS AND HEALTH ECONOMICS AND OUTCOME RESEARCH: A REVIEW OF APPLICATIONS AND CHALLENGES
Feb 25, 2026, 14:41 PM -
AI-ENABLED VIRTUAL REALITY REHABILITATION: A HEALTH ECONOMIC FRAMEWORK FOR NEURO-ONCOLOGY
Feb 25, 2026, 14:41 PM -
VARIATION IN CASGEVY AND LYFGENIA COVERAGE CRITERIA ACROSS STATE MEDICAID PLANS
Feb 25, 2026, 14:41 PM -
WHICH MEDICATION IS WITHDRAWN FIRST IN PATIENTS RECEIVING POLYPHARMACY? - A ANALYSIS USING HEALTH INSURANCE CLAIMS DATABASE
Feb 25, 2026, 14:41 PM -
CONCOMITANT USE OF DPP4 INHIBITORS AND RAAS INHIBITORS AND RISK OF ANGIOEDEMA: A RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:41 PM -
CHANGES IN GLP-1RA UTILIZATION TRENDS AMONG MALES AND FEMALES DURING 2019-2024: IMPACT OF SEMAGLUTIDE (WEGOVY) APPROVAL FOR CHRONIC WEIGHT MANAGEMENT
Feb 25, 2026, 14:41 PM -
SOCIODEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH TIME TO TREATMENT INITIATION AND CARE PATHWAYS IN NON-METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA: A REAL-WORLD EVIDENCE STUDY
Feb 25, 2026, 14:41 PM -
THE ICEBERG STUDY: VALIDATING PATIENT RIGHT OF ACCESS DATA COLLECTION AS A NOVEL METHOD FOR LONGITUDINAL RWD GENERATION IN CLINICAL RESEARCH
Feb 25, 2026, 14:41 PM -
PHYSICIAN-LED CHART ABSTRACTION (PLCA) IN ONCOLOGY: ADVANCING FDA FIT-FOR-USE REAL-WORLD DATA FOR HEOR DECISION-MAKING
Feb 25, 2026, 14:41 PM -
MEAN OVERALL SURVIVAL FROM THE PHASE 3 MIRASOL TRIAL OF MIRVETUXIMAB SORAVTANSINE VS INVESTIGATOR’S CHOICE OF CHEMOTHERAPY IN WOMEN WITH FR?-HIGH PLATINUM-RESISTANT OVARIAN CANCER (GOG 3045/ENGOT-OV55; NCT04209855)
Feb 25, 2026, 14:41 PM -
A SYSTEMATIC REVIEW OF FINDINGS AND METHODS IN ECONOMIC EVALUATIONS OF DYADIC HEALTHCARE INTERVENTIONS
Feb 25, 2026, 14:41 PM -
MODELLING THE COST-EFFECTIVENESS PROFILE OF RAPID GENOME SEQUENCING IN CHILDREN SUSPECTED OF RARE GENETIC DISEASES
Feb 25, 2026, 14:41 PM -
COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING
Feb 25, 2026, 14:41 PM -
BUILDING HIGH-QUALITY, RESEARCH-GRADE MULTI-SOURCE MORTALITY DATABASES IN A TIMELY MANNER
Feb 25, 2026, 14:41 PM -
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INDIVIDUALS INITIATING GLP-1 AGONISTS FOR OBESITY: A CLAIMS DATABASE ANALYSIS IN THE US
Feb 25, 2026, 14:41 PM -
ASSOCIATIONS OF GESTATIONAL DIABETES TREATMENT WITH MATERNAL WEIGHT CHANGE AND NEWBORN BIRTHWEIGHT
Feb 25, 2026, 14:41 PM -
PSYCHOMETRIC PERFORMANCE OF EQ-5D-5L INDEX IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA: EVIDENCE FROM PHASE III TRIAL DATA
Feb 25, 2026, 14:41 PM -
REAL-WORLD APPLICATION AND PERCEIVED EFFECTIVENESS OF INNOVATIVE ONCOLOGICAL MEDICINAL THERAPIES: A CROSS-SECTIONAL SURVEY OF ONCOLOGY SPECIALISTS
Feb 25, 2026, 14:41 PM -
ASSESSING GENERIC PREFERENCE-BASED MEASURES FOR PROGRESSIVE SUPRANUCLEAR PALSY: A CONCEPT MAPPING APPROACH
Feb 25, 2026, 14:41 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH SYSTEMIC INFLAMMATION IN PATIENTS WITH CORONARY HEART DISEASE AND CHRONIC KIDNEY DISEASE: A RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:41 PM
